Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Atopic dermatitis (AD) primarily affects infants and young children. Although topical corticosteroids (TCSs) are often prescribed, noncorticosteroid treatments are needed because compliance with TCSs is poor due to concerns about their side effects. In this longest and largest intervention study ever conducted in infants with mild-to-moderate AD, pimecrolimus 1% cream (PIM) was compared with TCSs. Methods: A total of 2418 infants were enrolled in this 5-year open-label study. Infants were randomized to PIM (n = 1205; with short-term TCSs for disease flares) or TCSs (n = 1213). The primary objective was to compare safety; the secondary objective was to document PIM’s long-term efficacy. Treatment success was defined as an Investigator’s Global Assessment score of 0 (clear) or 1 (almost clear). Results: Both PIM and TCSs had a rapid onset of action with >50% of patients achieving treatment success by week 3. After 5 years, >85% and 95% of patients in each group achieved overall and facial treatment success, respectively. The PIM group required substantially fewer steroid days than the TCS group (7 vs 178). The profile and frequency of adverse events was similar in the 2 groups; in both groups, there was no evidence for impairment of humoral or cellular immunity. Conclusions: Long-term management of mild-to-moderate AD in infants with PIM or TCSs was safe without any effect on the immune system. PIM was steroid-sparing. The data suggest PIM had similar efficacy to TCS and support the use of PIM as a first-line treatment of mild-to-moderate AD in infants and children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atopic dermatitis and the atopic march
Spergel, J. M., & Paller, A. S. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.09.033 · Cited by 1,229
Self-citationLEWIS-JONES, S. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01047.x · Cited by 478
Quality of life of children with atopic dermatitis and their families
McKenna, S. P., & Doward, L. C. (2008) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0b013e3282ffd6cc · Cited by 74
Cited by
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Self-citationWollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Self-citationWollenberg, A., Oranje, A., Deleuran, M., Simon, D., Szalai, Z., Kunz, B., Svensson, A., Barbarot, S., von Kobyletzki, L., Taieb, A., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13599 · Cited by 395
Self-citationAtopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Boguniewicz, M., Fonacier, L., Guttman-Yassky, E., Ong, P. Y., Silverberg, J., & Farrar, J. R. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2017.10.039 · Cited by 305
Self-citation
Metadata
- Authors
- Sigurgeirsson, B., Boznanski, A., Todd, G., Vertruyen, A., Schuttelaar, M.-L. A., Zhu, X., Schauer, U., Qaqundah, P., Poulin, Y., Kristjansson, S., von Berg, A., Nieto, A., Boguniewicz, M., Paller, A. S., Dakovic, R., Ring, J., & Luger, T.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2015-04-01
- Volume
- 135
- Issue
- 4
- Pages
- 597-606
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2120892346
- Cited by
- 149
- References
- 3
- FWCI
- 18.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial. https://app.cochat.ai/papers/10.1542/peds.2014-1990
- The paper
- Sigurgeirsson, B., Boznanski, A., Todd, G., Vertruyen, A., Schuttelaar, M.-L. A., Zhu, X., Schauer, U., Qaqundah, P., Poulin, Y., Kristjansson, S., von Berg, A., Nieto, A., Boguniewicz, M., Paller, A. S., Dakovic, R., Ring, J., & Luger, T. (2015). Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial. Pediatrics. https://doi.org/10.1542/peds.2014-1990
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.